For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Scope of the Report:
This report focuses on the Hyperimmune Globulins in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
In the last several years, global market of Hyperimmune Globulins developed rapidly, with an average growth rate of 6%. In 2017, global revenue of Hyperimmune Globulins is nearly 1150 million USD; the actual production is about 40 million units.
The classification includes the Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins and others, and the proportion of Rabies Immunoglobulins in 2017 is about 44.2%, with the largest market share.
Hyperimmune Globulins is widely used in Government Institutions, Private Sector and Other. The most proportion of Hyperimmune Globulins is sold in Government Institutions, and the proportion in 2017 is about 62.7%.
The worldwide market for Hyperimmune Globulins is expected to grow at a CAGR of roughly 9.7% over the next five years, will reach 1960 million US$ in 2023, from 1120 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- CSL Behring
- Emergent (Cangene)
- Hualan Bio
- Shanghai RAAS
- Sichuan Yuanda Shuyang
- ADMA Biologics
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Hepatitis B Immunoglobulins
- Rabies Immunoglobulins
- Tetanus Immunoglobulins
Market Segment by Applications, can be divided into
- Government Institutions
- Private Sector
There are 15 Chapters to deeply display the global Hyperimmune Globulins market.
Chapter 1, to describe Hyperimmune Globulins Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Hyperimmune Globulins, with sales, revenue, and price of Hyperimmune Globulins, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Hyperimmune Globulins, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Hyperimmune Globulins market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Hyperimmune Globulins sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source